[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fay1NzxrWwgxvlEFE46RDqnBvq5utkMqizZjDx1X6UGc":8,"$fhI9fu-wGZS21hModiS3xFueTxxHXAVFN4y1aC1bJ_Co":55,"$fJcyhBHL3LLFxodEx3Gqqxfohbm86w50jncR0bjmkAYE":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},65592,869732,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//qvhCCTIvcNBh6P1V3cjuUDfxcVOObxse.png","杨丰名","浙江大学医学院附属第二医院","肿瘤科","主治医师",41,0,"下肢恶性肿瘤维持性化学治疗用药安全指南","","https://ystcdn.venuertc.com/venue/AI/5c4c801a-90c2-4225-9f89-8da73a1b4cfe.jpg","\u003Cdiv id=\"material_title\" class=\"material-title\">\n  下肢恶性肿瘤维持性化学治疗用药安全指南\n\u003C/div>\n\u003Cdiv class=\"material-section material-section-bg1\">\n  \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">什么是下肢恶性肿瘤维持性化学治疗？💊\u003C/h2>\n  \u003Cdiv class=\"material-content\">\n    \u003Cp>\n      说起来，下肢恶性肿瘤的化学治疗主要依赖几种特殊药品进行长期维持。以脂质体蒽环类药物为代表，联合阿瑞匹坦、聚乙二醇化重组人粒细胞刺激因子等。在实际用药过程中，要关注剂型选择、正确用法以及避免常见风险。本文将从\u003Cspan style=\"font-weight:bolder;\">7个关键细节\u003C/span>为大家详细讲解相关药品的使用方法和注意事项，帮助您更安全、合理地用药。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"material-section material-section-bg2\">\n  \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">脂质体多柔比星注射液——核心药品信息🧪\u003C/h2>\n  \u003Cdiv class=\"material-content\">\n    \u003Cul>\n      \u003Cli>\u003Cstrong>主要成分：\u003C/strong>盐酸多柔比星，以脂质体包裹剂型制备。\u003C/li>\n      \u003Cli>\u003Cstrong>剂型：\u003C/strong>注射液，需经静脉输注。\u003C/li>\n      \u003Cli>\u003Cstrong>规格：\u003C/strong>常见每瓶10mg、20mg、多规格分装。\u003C/li>\n      \u003Cli>\u003Cstrong>药理机制：\u003C/strong>通过嵌入肿瘤细胞DNA，干扰细胞分裂。“脂质体”包裹减少心脏毒性。\u003C/li>\n      \u003Cli>\u003Cstrong>适应症：\u003C/strong>可用于部分恶性肿瘤的维持性化学治疗。\u003C/li>\n    \u003C/ul>\n    \u003Cp>对比传统多柔比星，脂质体制剂在分布与毒副反应方面有明显优化。聚焦于药品本身，合理选型和严格剂量管理是用药安全的关键。\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"material-section material-section-bg3\">\n  \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">正确使用脂质体多柔比星注射液的6个要点✨\u003C/h2>\n  \u003Cdiv class=\"material-content\">\n    \u003Col>\n      \u003Cli>\n        \u003Cstrong>静脉输注方式：\u003C/strong>\u003Cbr>\n        需经静脉缓慢滴注，不可推注或快速输入。正确做法是：每次注射按医嘱配置，使用输液泵控制速度。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>剂量管控：\u003C/strong>\u003Cbr>\n        必须严格按照医生处方剂量使用，不私自加量减量。老年人或体重偏低者需由专业人员调整剂量。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>注射时间：\u003C/strong>\u003Cbr>\n        每次给药前后应充足补液，减轻药物对静脉的刺激。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>复溶方法：\u003C/strong>\u003Cbr>\n        不建议用力摇晃，应用轻柔倒置混匀，保证脂质体结构完整。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>配伍溶液：\u003C/strong>\u003Cbr>\n        推荐用葡萄糖注射液，而非生理盐水。葡萄糖更适合脂质体制剂稳定性。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>遗忘与过量：\u003C/strong>\u003Cbr>\n        如漏服需尽快联系医护人员，不要自行补药；如过量，必须立即就医。\n      \u003C/li>\n    \u003C/ol>\n    \u003Cp>临床实践中，67岁女性患者接受脂质体多柔比星维持治疗，严格遵守注射标准后未出现明显不良反应。可见流程规范对于用药安全至关重要。\u003Cspan class=\"material-mark\">（用药案例仅一次引用）\u003C/span>\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"material-section material-section-bg4\">\n  \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">脂质体多柔比星的药物相互作用🔄\u003C/h2>\n  \u003Cdiv class=\"material-content\">\n    \u003Cul>\n      \u003Cli>不可与\u003Cstrong>氯化钠注射液\u003C/strong>直接配伍，易导致制剂不稳定。\u003C/li>\n      \u003Cli>避免与\u003Cstrong>已知心脏毒性药物\u003C/strong>（如环磷酰胺）同用，心脏负担加重。\u003C/li>\n      \u003Cli>在\u003Cspan style=\"color:#508475;\">化疗期间\u003C/span>，勿联合其他蒽环类药物，防止累计毒性。\u003C/li>\n      \u003Cli>与强抑酸药同用可能影响药物代谢，需医师综合评估。\u003C/li>\n    \u003C/ul>\n    \u003Cp>正确做法：所有合并用药必须提前咨询医生和药师，落实交互风险监控。\u003C/p>\n    \u003Cp>\n      \u003Cspan class=\"material-emojimark\">📊\u003C/span>\n      临床研究显示，脂质体多柔比星制剂的心脏毒性发生率明显低于传统多柔比星，约为2.2%\n      \u003Cspan class=\"material-data\">（参考：Mross K et al., 2012）\u003C/span>。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"material-section material-section-bg5\">\n  \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">脂质体多柔比星常见不良反应与处理办法⚠️\u003C/h2>\n  \u003Cdiv class=\"material-content\">\n    \u003Col>\n      \u003Cli>\n        \u003Cstrong>口腔黏膜反应：\u003C/strong>\n        \u003Cbr>\n        正确做法：勤漱口、保持口腔清洁，如严重应及时就医。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>手足皮肤红斑：\u003C/strong>\n        \u003Cbr>\n        常在用药周期后出现。可通过保湿护理和减少摩擦缓解。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>脱发：\u003C/strong>\n        \u003Cbr>\n        通常不可逆转，但多数患者可恢复。建议护理头皮，避免刺激性洗剂。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>心脏毒性：\u003C/strong>\n        \u003Cbr>\n        极少见但较严重，定期检测心功能，发现异常必须停药并就诊。\n      \u003C/li>\n    \u003C/ol>\n    \u003Cp>\n      \u003Cspan class=\"material-emojimark\">🔍\u003C/span>\n      说明书提示，口腔黏膜炎症发生率约为18%，但多为轻～中度。\n      \u003Cbr>出现严重反应时，不能自行停药，需专业处理。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"material-section material-section-bg6\">\n  \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">脂质体多柔比星的储存和有效期📦\u003C/h2>\n  \u003Cdiv class=\"material-content\">\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>储存温度：\u003C/strong>应保持在2-8℃，不可冷冻。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>防光防潮：\u003C/strong>采用原包装避光储存，严禁暴晒和受潮。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>开封有效期：\u003C/strong>注射液配制后最长24小时内使用，剩余药品不可再用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>过期药品处理：\u003C/strong>交由医疗机构按危险品处理，勿自行丢弃。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>正确做法：家庭储存尤其要注意低温和避光，确保药品质量可靠。\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"material-section material-section-bg7\">\n  \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">阿瑞匹坦胶囊的用药细节🌟\u003C/h2>\n  \u003Cdiv class=\"material-content\">\n    \u003Cul>\n      \u003Cli>\u003Cstrong>成分及剂型：\u003C/strong>阿瑞匹坦，胶囊口服，每粒常见规格80mg/125mg。\u003C/li>\n      \u003Cli>\u003Cstrong>作用机制：\u003C/strong>通过阻断神经递质，减少化疗引发的恶心呕吐。\u003C/li>\n      \u003Cli>\u003Cstrong>正确服用时间：\u003C/strong>应在化疗前或按医嘱提前服用，一般于餐前空腹服用效果较佳。\u003C/li>\n      \u003Cli>\u003Cstrong>服药方式：\u003C/strong>整个胶囊吞服，不要咬碎，配足量水。\u003C/li>\n      \u003Cli>\u003Cstrong>剂量与疗程：\u003C/strong>首日剂量较高，化疗期间遵医嘱调整，不可自行加减。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"material-emojimark\">☑️\u003C/span>\n      有位肿瘤患者依照剂量分步服用阿瑞匹坦后，未发生严重呕吐，体验效果显著。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"material-section material-section-bg8\">\n  \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">阿瑞匹坦的相互作用与注意事项🔔\u003C/h2>\n  \u003Cdiv class=\"material-content\">\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>避免合用：\u003C/strong>\n        与\u003Cstrong>华法林\u003C/strong>、部分抗癫痫药（如苯妥英）等同用时需特别警觉，会影响凝血功能或药物代谢。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>与口服避孕药：\u003C/strong>\n        可能影响避孕效果，应采取额外措施。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>饮食关系：\u003C/strong>\n        部分食物如葡萄柚可增加阿瑞匹坦血药浓度，不建议同时食用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>肝肾功能障碍：\u003C/strong>\n        需由医生评估剂量及使用安全性。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"material-emojimark\">💡\u003C/span>\n      数据表明，阿瑞匹坦引发头痛、疲倦等不良反应概率约在7%左右，绝大多数可耐受。\n      \u003Cspan class=\"material-data\">（参考：Navari RM, 2015）\u003C/span>\n    \u003C/p>\n    \u003Cp>\n      正确做法：所有并用药物必须将药品清单提供给医生，每种药品交互都需储备详细信息，无遗漏。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"material-section material-section-bg9\">\n  \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">升白细胞药品：聚乙二醇化重组人粒细胞刺激因子注射液🧬\u003C/h2>\n  \u003Cdiv class=\"material-content\">\n    \u003Cul>\n      \u003Cli>\u003Cstrong>成分：\u003C/strong>聚乙二醇化重组人粒细胞刺激因子\u003C/li>\n      \u003Cli>\u003Cstrong>剂型：\u003C/strong>预充注射器，皮下注射，规格多为3mg/6mg。\u003C/li>\n      \u003Cli>\u003Cstrong>作用机制：\u003C/strong>促进骨髓白细胞生成，提高化疗期间免疫力。\u003C/li>\n      \u003Cli>\u003Cstrong>使用时机与方法：\u003C/strong>通常应在化疗药物注射后24-72小时皮下注射，每次单独使用。\u003C/li>\n      \u003Cli>\u003Cstrong>特殊注意：\u003C/strong>不可静脉注射，不与其他药品混用。\u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"material-emojimark\">🧡\u003C/span>\n      有患者因白细胞下降，遵医嘱使用该药，顺利度过用药周期，没有发生严重感染。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"material-section material-section-bg10\">\n  \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">聚乙二醇化重组人粒细胞刺激因子的副作用及对应方案🛡️\u003C/h2>\n  \u003Cdiv class=\"material-content\">\n    \u003Col>\n      \u003Cli>\n        \u003Cstrong>骨痛或肌肉痛：\u003C/strong>\n        多为轻度，可用常见非处方止痛药缓解，如持续超过3天建议咨询医生。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>低热：\u003C/strong>\n        如体温略有升高，观察即可，超过38.5℃需就诊。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>过敏反应：\u003C/strong>\n        极少见，有皮疹、气促等立即停药并送医处理。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>注射局部反应：\u003C/strong>\n        皮肤红肿、刺痛等，适当冷敷可缓解。\n      \u003C/li>\n    \u003C/ol>\n    \u003Cp>\n      \u003Cspan class=\"material-emojimark\">📈\u003C/span>\n      临床数据显示，该药急性过敏反应发生率低于0.5%，但仍需严格监测。\n      \u003Cspan class=\"material-data\">（参考：Bondarenko I et al., 2019）\u003C/span>\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"material-section material-section-bg11\">\n  \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">辅助药品与特殊人群用药建议🌱\u003C/h2>\n  \u003Cdiv class=\"material-content\">\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>基础疾病管理药品：\u003C/strong>\n        如二甲双胍、DPP-4抑制剂、调脂药等药品，仅按医生指示使用，不随意减停。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>神经营养药品：\u003C/strong>\n        用于缓解因化疗相关的神经不适，一般为补充维生素B族及营养剂型，无需加量。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>中药制剂与穴位贴敷：\u003C/strong>\n        必须报告给医生，避免与西药发生未知相互作用。勿自行更换用药顺序。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>老年患者：\u003C/strong>\n        各项药品剂量需个体化，根据肝肾功能和综合状况精细调整。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>特殊群体：\u003C/strong>\n        孕产妇及儿童应避免使用化疗、升白药品，具体以指导为准。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>临床案例显示：合并用药时，明确用药清单、规范用药计划对避免风险至关重要。\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"material-section material-section-bg12\">\n  \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">结语：安全用药核心建议📝\u003C/h2>\n  \u003Cdiv class=\"material-content\">\n    \u003Cp>\n      通过规范使用脂质体多柔比星、阿瑞匹坦、升白药品以及辅助用药措施，大幅提升维持治疗的安全性和治疗效果。\u003Cbr>\n      \u003Cspan class=\"material-emojimark\">😉\u003C/span>\n      \u003Cspan style=\"font-weight:bolder;\">最需记住的两点：\u003C/span>药品必须按医嘱严格使用，每次更换药品或剂量前咨询医生与药师。留心药品交互和不良反应，出现疑问或异常及时就医。合理保存药品、规范管理周期，是每位患者和家属的责任。\u003Cbr>\n      只有这样，才能充分发挥药品功效 并规避风险，保障治疗顺利进行。\n    \u003C/p>\n    \u003Cdiv class=\"material-citation\">\n      \u003Cstrong>参考文献：\u003C/strong>\u003Cbr>\n      \u003Cspan class=\"material-ref\">\n        Mross, K., et al. (2012). \"Pharmacokinetics and safety of liposomal doxorubicin.\" Cancer Chemotherapy and Pharmacology, 69(5), 1199–1211. \u003Cbr>\n        Navari, R. M. (2015). \"Aprepitant for the prevention of chemotherapy-induced nausea and vomiting.\" Expert Review of Clinical Pharmacology, 8(6), 671–676. \u003Cbr>\n        Bondarenko, I., et al. (2019). \"Safety and efficacy of pegfilgrastim in cancer patients receiving chemotherapy.\" Supportive Care in Cancer, 27(3), 1059–1067.\n      \u003C/span>\n    \u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.material-title {\n  font-size:32px;\n  font-weight:bold;\n  color:#256796;\n  margin:40px 0 22px 0;\n  text-align:center;\n  letter-spacing:2px;\n}\n.material-section {\n  padding:28px 34px 28px 34px;\n  border-radius:22px;\n  margin-bottom:33px;\n  box-sizing:border-box;\n  max-width:800px;\n  margin-left:auto;\n  margin-right:auto;\n  background:#fafcff;\n  box-shadow:0px 4px 20px rgba(190, 210, 225, 0.14);\n}\n\n.material-section-bg1 {\n  background:linear-gradient(110deg, #e3eeff 60%, #fafdff 100%);\n}\n.material-section-bg2 {\n  background: linear-gradient(125deg, #e9ecef 90%, #f6fbfb 100%);\n}\n.material-section-bg3 {\n  background: linear-gradient(110deg, #ebe6f6 75%, #fafdff 100%);\n}\n.material-section-bg4 {\n  background: linear-gradient(115deg, #e6f3e7 60%, #fafdff 100%);\n}\n.material-section-bg5 {\n  background: linear-gradient(125deg, #fdeee6 90%, #f6fbfb 100%);\n}\n.material-section-bg6 {\n  background: linear-gradient(120deg, #e2eaf2 50%, #fafdff 100%);\n}\n.material-section-bg7 {\n  background: linear-gradient(105deg, #fcf1f3 75%, #fafdff 100%);\n}\n.material-section-bg8 {\n  background: linear-gradient(120deg, #f3f6e6 60%, #fafdff 100%);\n}\n.material-section-bg9 {\n  background: linear-gradient(125deg, #e6f2f8 90%, #f6fbfb 100%);\n}\n.material-section-bg10 {\n  background: linear-gradient(110deg, #f5f3e7 75%, #fafdff 100%);\n}\n.material-section-bg11 {\n  background: linear-gradient(115deg, #e8f2ee 60%, #fafdff 100%);\n}\n.material-section-bg12 {\n  background: linear-gradient(120deg, #f9e8e6 50%, #fafdff 100%);\n}\n\n.material-subtitle {\n  font-size:23px;\n  font-weight:700;\n  color:#2c526e;\n  margin-bottom:13px;\n  background:rgba(250,255,253,0.37);\n  padding:12px 18px;\n  border-radius:10px;\n  display:inline-block;\n  box-shadow:0px 2px 6px rgba(225,220,255,0.04);\n}\n.material-content {\n  font-size:17px;\n  color:#223344;\n  margin-top:4px;\n}\n.material-content ul, .material-content ol {\n  margin-top:9px;\n  margin-bottom:18px;\n  padding-left:24px;\n}\n.material-content li {\n  margin-bottom:6px;\n  line-height:1.6em;\n}\n.material-mark {\n  color:#297DAC;\n  font-size:16px;\n}\n.material-emojimark {\n  font-size:20px;\n  margin-right:4px;\n}\n.material-citation {\n  margin-top:15px;\n  padding:10px 16px;\n  background: #f5f9fa;\n  border-left:5px solid #afbed4;\n  font-size:15px;\n  color:#34556a;\n  border-radius:8px;\n}\n.material-ref {\n  font-size:15px;\n  color:#255880;\n  display:block;\n  margin-top:7px;\n}\n.material-data {\n  font-size:16px;\n  color:#6a9eb3;\n}\n\u003C/style>\n","\u003Cdiv id=\"material_title\" class=\"material-title\">\n  下肢恶性肿瘤维持性化学治疗用药安全指南\n\u003C/div>\n\u003Cdiv class=\"material-s",517,"2025-09-03 15:25:44","下肢恶性肿瘤, 化学治疗, 脂质体多柔比星, 阿瑞匹坦, 药物安全","了解下肢恶性肿瘤维持性化学治疗的核心药品、使用技巧和不良反应处理。本指南为患者提供安全用药建议，保障治疗效果。","2025-09-08 14:10:34",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]